AHF: Gilead Sciences, Inc. (GILD)’s Stribild Not Covered by NY Medicaid; State Also Explores ‘Prior Auth’ Status for AIDS Drug  
9/24/2012 10:12:50 AM

WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) today reported that the New York State Department of Health’s Medicaid program does NOT cover Gilead Sciences’ expensive new AIDS drug Stribild, its new four-in-one treatment combination, which was approved by the Food and Drug Administration (FDA) in early September and then immediately priced by Gilead at $28,500 per patient, per year, Wholesale Acquisition Cost (WAC). That price was over 35% more than Atripla, the company’s best selling combination HIV/AIDS treatment, and made Stribild the highest priced first line combination AIDS therapy.